Kazia Therapeutics says diversification is the key to drug development

Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas.


Kazia Therapeutics’ oncology drug paxalisib continues to generate positive trial data

Kazia Therapeutics CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases.


Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference

Interim data from the study reveals a complete or partial response in all evaluable trial participants for a disease with a poor prognosis and limited current options.